Compare · HIMS vs LFMD
HIMS vs LFMD
Side-by-side comparison of Hims & Hers Health Inc. (HIMS) and LifeMD Inc. (LFMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HIMS and LFMD operate in Medical/Nursing Services (Health Care), so they compete in similar markets.
- HIMS is the larger of the two at $7.41B, about 47.3x LFMD ($156.7M).
- HIMS has been more active in the news (24 items in the past 4 weeks vs 8 for LFMD).
- HIMS has more recent analyst coverage (25 ratings vs 11 for LFMD).
- Company
- Hims & Hers Health Inc.
- LifeMD Inc.
- Price
- -
- -
- Market cap
- $7.41B
- $156.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Nursing Services
- Medical/Nursing Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 24
- 8
- Recent ratings
- 25
- 11
Hims & Hers Health Inc.
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available for purchase on its websites directly by customers. It provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, as well as cosmetics and supplement products, primarily focusing on wellness, sexual health, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, collagen protein, biotin, and teas in the wellness category; moisturizer, fragrances, face wash, and anti-wrinkle creams in the skincare category; condoms and lubricants in the sexual health category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. It also offers medical consultation services; and engages in the wholesale of non-prescription product sales to retailers. Hims & Hers Health, Inc. is based in San Francisco, California.
LifeMD Inc.
LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including concierge care, men's sexual health, dermatology, and others in the United States. The company provides ShapiroMD, a medical device for male and female hair loss; RexMD, a men's telehealth brand that offers virtual medical treatment from licensed providers for a variety of men's health needs; Nava MD, a female-oriented tele-dermatology and skincare brand that would offer virtual medical treatment from dermatologists and other providers; and iNR Wellness MD, a supplement for immune and digestive support. It also offers PDFSimpli, an online software-as-a-service platform that allows users to create, edit, convert, sign, and share PDF documents. LifeMD sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is based in New York, New York.
Latest HIMS
- Chief Policy Officer Autor Deborah M. sold $467,128 worth of shares (16,773 units at $27.85) as part of a pre-agreed trading plan, decreasing direct ownership by 26% to 48,961 units (SEC Form 4)
- Chief Financial Officer Okupe Oluyemi sold $148,111 worth of shares (4,938 units at $29.99) as part of a pre-agreed trading plan and exercised 4,938 shares at a strike of $5.01 (SEC Form 4)
- Chief Legal Officer Boughton Soleil sold $691,808 worth of shares (25,111 units at $27.55) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 313,964 units (SEC Form 4)
- Chief Legal Officer Boughton Soleil converted options into 42,261 shares and covered exercise/tax liability with 21,500 shares, increasing direct ownership by 7% to 339,075 units (SEC Form 4) to satisfy tax liability
- Chief Medical Officer Carroll Patrick Harrison converted options into 26,187 shares and covered exercise/tax liability with 10,201 shares, increasing direct ownership by 9% to 197,847 units (SEC Form 4) (for tax liability)
- Director Schultz Kare converted options into 6,623 shares, increasing direct ownership by 34% to 26,020 units (SEC Form 4)
- Chief Policy Officer Autor Deborah M. converted options into 32,920 shares and covered exercise/tax liability with 16,147 shares, increasing direct ownership by 34% to 65,734 units (SEC Form 4) to satisfy withholding tax
- CTO Elshenawy Mohamed converted options into 188,285 shares and covered exercise/tax liability with 95,798 shares, increasing direct ownership by 92% to 193,510 units (SEC Form 4) (tax withholding)
- Chief Operating Officer Chi Michael converted options into 86,265 shares and covered exercise/tax liability with 47,702 shares, increasing direct ownership by 9% to 470,687 units (SEC Form 4) to satisfy withholding obligation
- Chief Executive Officer Dudum Andrew converted options into 154,993 shares and covered exercise/tax liability with 78,859 shares, increasing direct ownership by 8% to 1,033,177 units (SEC Form 4) to satisfy withholding obligation
Latest LFMD
- Director Larovere Joan was granted 35,000 shares, increasing direct ownership by 33% to 142,050 units (SEC Form 4)
- Director Strawn John R Jr was granted 85,000 shares, increasing direct ownership by 21% to 498,001 units (SEC Form 4)
- Director Ditrolio Joseph was granted 35,000 shares, increasing direct ownership by 13% to 308,413 units (SEC Form 4)
- Amendment: Director Simon Roberto was granted 80,810 shares, increasing direct ownership by 81% to 180,810 units (SEC Form 4)
- Director Simon Roberto was granted 85,000 shares, increasing direct ownership by 42% to 288,175 units (SEC Form 4)
- Director Macrae Calum Archibald was granted 35,000 shares, increasing direct ownership by 90% to 73,865 units (SEC Form 4)
- SEC Form 10-Q filed by LifeMD Inc.
- LifeMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- LifeMD to Report Second Quarter 2026 Financial Results on August 5
- LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock